Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Entrectinib is an oral multikinase inhibitor that target Proto-oncogene tyrosine-protein kinase ROS (ROS1); it has been evaluated in advanced Non-small-cell lung cancer (NSCLC) (ROS1 +) in single-arm phase I–II clinical trials that supported regulatory approvals. It is approved by the FDA in 2019 and by the EMA in 2020 (1-6). [Crizotinib & Non-small-cell lung cancer (NSCLC) (ROS1 +)](brain://udPEr8IEs1GBzb4CEJFkEQ/CrizotinibNonsmallcellL…